References

  1. 1.Volpicelli JR, Menzies P. Rethinking unhealthy alcohol use in the United States: a structured review. Subst Abuse. 2022;16:11782218221111832.
  2. 2.National Institute on Alcohol Abuse and Alcoholism. Drinking levels and patterns defined. https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/moderate-binge-drinking
  3. 3.Dietary Guidelines for Americans, 2020-2025. 9th ed. US Dept of Agriculture; 2020. https://www.dietaryguidelines.gov/alcohol/info
  4. 4.World Health Organization. No level of alcohol consumption is safe for our health. https://www.who.int/europe/news/item/04-01-2023-no-level-of-alcohol-consumption-is-safe-for-our-health
  5. 5.Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text revision. American Psychiatric Association; 2022.
  6. 6.Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(18):1899-1909.
  7. 7.Chatterton B, Agnoli A, Schwarz EB, et al. Alcohol screening during US primary care visits, 2014-2016. J Gen Intern Med. 2022;37(15):3848-3852.
  8. 8.Rosário F, Santos MI, Angus K, et al. Factors influencing the implementation of screening and brief interventions for alcohol use in primary care practices: a systematic review using the COM-B system and Theoretical Domains Framework. Implement Sci. 2021;16:6.
  9. 9.Tan CH, Hungerford DW, Denny CH, et al. Screening for alcohol misuse: practices among U.S. primary care providers, DocStyles 2016. Am J Prev Med. 2018;54(2):173-180.
  10. 10.Senthilkumar H, Haidar AA, Kauffman B, et al. Increasing alcohol screening and brief intervention rates using the office champions model in family medicine practices. Fam Pract Manag. 2022;29(4):25-30.
  11. 11.American Academy of Family Physicians. AAFP updates alcohol use practice manual. https://www.aafp.org/news/health-of-the-public/alcohol-substance-use-resources.html
  12. 12.Hargraves D, White C, Frederick R, et al. Implementing SBIRT (screening, brief intervention and referral to treatment) in primary care: lessons learned from a multi-practice evaluation portfolio. Public Health Rev. 2017;38:31.
  13. 13.Substance Abuse and Mental Health Services Administration. TAP 33: systems-level implementation of screening, brief intervention, and referral to treatment (SBIRT). https://store.samhsa.gov/product/tap-33-systems-level-implementation-screening-brief-intervention-and-referral-treatment
  14. 14.Ray LA, Bujarski S, Grodin E, et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45(2):124-140.
  15. 15.National Institute on Alcohol Abuse and Alcoholism. Screen and assess: use quick, effective methods. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/screen-and-assess-use-quick-effective-methods
  16. 16.Substance Abuse and Mental Health Services Administration. Screening, brief intervention, and referral to treatment (SBIRT). https://www.samhsa.gov/sbirt
  17. 17.National Institute on Alcohol Abuse and Alcoholism. Alcohol use disorder (AUD) in the United States: age groups and demographic characteristics. https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics
  18. 18.Tucker JA, Chandler SD, Witkiewitz K. Epidemiology of recovery from alcohol use disorder. Alcohol Res. 2020;40(3):02.
  19. 19.White AM. Gender differences in the epidemiology of alcohol use and related harms in the United States. Alcohol Res. 2020;40(2):01.
  20. 20.Zhang H, Ruan WJ, Chou SP, et al. Exploring patterns of alcohol use and alcohol use disorder among Asian Americans with a finer lens. Drug Alcohol Depend. 2024;257:111120.
  21. 21.Centers for Disease Control and Prevention. What is excessive drinking? https://www.cdc.gov/drink-less-be-your-best/excessive-drinking.html
  22. 22.National Institute on Drug Abuse. LGBTQI+ people and substance use. https://nida.nih.gov/research-topics/substance-use-suds-in-lgbtq-populations
  23. 23.Hughes TL, Wilsnack SC, Kantor LW. The influence of gender and sexual orientation on alcohol use and alcohol-related problems. Alcohol Res. 2016;38(1):121-132.
  24. 24.Schuckit MA. AUD risk, diagnoses, and course in a prospective study across two generations: implications for prevention. Alcohol Res. 2022;42(1):01.
  25. 25.Anthenelli R, Grandison L. Effects of stress on alcohol consumption. Alcohol Res. 2012;34(4):381-382.
  26. 26.McHugh R. Alcohol use disorder and depressive disorders. Alcohol Res. 2019;40(1):arcr.v40.1.01.
  27. 27.Ferrie ML, Lheureux A, Vujanovic AA, et al. Co-occurring posttraumatic stress disorder symptoms and alcohol use behaviors: the mediating role of drinking to cope with PTSD symptoms. J Dual Diagn. 2023;19(4):221-230.
  28. 28.The ASAM clinical practice guideline on alcohol withdrawal management. J Addict Med. 2020;14(3S suppl 1):1-72.
  29. 29.Tiglao SM, Meisenheimer ES, Oh RC. Alcohol withdrawal syndrome: outpatient management. Am Fam Physician. 2021;104(3):253-262.
  30. 30.Pribék IK, Kovács I, Kádár BK, et al. Evaluation of the course and treatment of alcohol withdrawal syndrome with the Clinical Institute Withdrawal Assessment for Alcohol—Revised: a systematic review-based meta-analysis. Drug Alcohol Depend. 2021;220:108536.
  31. 31.World Health Organization. Global status report on alcohol and health 2018. https://www.who.int/publications-detail-redirect/9789241565639
  32. 32.Haber PS, Kortt NC. Alcohol use disorder and the gut. Addiction. 2021;116(3):658-667.
  33. 33.National Cancer Institute. Alcohol and cancer risk. https://www.cancer.gov/about-cancer/causes-prevention/risk/alcohol/alcohol-fact-sheet
  34. 34.Hoek AG, van Oort S, Mukamal KJ, et al. Alcohol consumption and cardiovascular disease risk: placing new data in context. Curr Atheroscler Rep. 2022;24(1):51-59.
  35. 35.Wood AM, Kaptoge S, Butterworth AS, et al.; Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018;391(10129):1513-1523.
  36. 36.Levesque C, Sanger N, Edalati H, et al. A systematic review of relative risks for the relationship between chronic alcohol use and the occurrence of disease. Alcohol Clin Exp Res (Hoboken). 2023;47(7):1238-1255.
  37. 37.Biddinger KJ, Emdin CA, Haas ME, et al. Association of habitual alcohol intake with risk of cardiovascular disease. JAMA Netw Open. 2022;5(3):e223849.
  38. 38.Krittanawong C, Isath A, Rosenson RS, et al. Alcohol consumption and cardiovascular health. Am J Med. 2022;135(10):1213-1230.
  39. 39.Dejong K, Olyaei A, Lo JO. Alcohol use in pregnancy. Clin Obstet Gynecol. 2019;62(1):142-155.
  40. 40.Centers for Disease Control and Prevention. Fetal alcohol spectrum disorders (FASDs). What CDC is doing. https://www.cdc.gov/fasd/about/cdc-efforts.html
  41. 41.Tian YM, Zhang WS, Jiang CQ, et al. Association of alcohol use with memory decline in middle-aged and older Chinese: a longitudinal cohort study. BMC Psychiatry. 2022;22(1):673.
  42. 42.Covell T, Siddiqui W. Korsakoff syndrome. StatPearls. http://www.ncbi.nlm.nih.gov/books/NBK539854/
  43. 43.Centers for Disease Control and Prevention. Alcohol use and your health. https://www.cdc.gov/alcohol/about-alcohol-use/
  44. 44.Alpert HR, Slater ME, Yoon YH, et al. Alcohol consumption and 15 causes of fatal injuries: a systematic review and meta-analysis. Am J Prev Med. 2022;63(2):286-300.
  45. 45.Witkiewitz K, Tucker JA. Abstinence not required: expanding the definition of recovery from alcohol use disorder. Alcohol Clin Exp Res. 2020;44(1):36-40.
  46. 46.Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815-824.
  47. 47.Dellazizzo L, Potvin S, Giguère S, et al. Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders. Psychiatry Res. 2023;326:115318.
  48. 48.McCrady BS, Flanagan JC. The role of the family in alcohol use disorder recovery for adults. Alcohol Res. 2021;41(1):06.
  49. 49.Kelly JF, Humphreys K, Ferri M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst Rev. 2020(3):CD012880.
  50. 50.Colditz JB, Chu KH, Hsiao L, et al. Characterizing online social support for alcohol use disorder: a mixed-methods approach. Alcohol Clin Exp Res (Hoboken). 2023;47(11):2110-2120.
  51. 51.Kowalchuk A, Gonzalez SJ, Zoorob RJ. Substance misuse in adults: a primary care approach. Am Fam Physician. 2024;109(5):430-440.
  52. 52.Kranzler HR, Hartwell EE. Medications for treating alcohol use disorder: a narrative review. Alcohol Clin Exp Res (Hoboken). 2023;47(7):1224-1237.
  53. 53.Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Focus (Am Psychiatr Publ). 2019;17(2):158-162.
  54. 54.Poorman E, McQuade BM, Messmer S. Medications for alcohol use disorder. Am Fam Physician. 2024;109(1):71-78.
  55. 55.Piché F, Daneau C, Plourde C, et al. Characteristics and impact of physical activity interventions during substance use disorder treatment excluding tobacco: a systematic review. PLoS One. 2023;18(4):e0283861.
  56. 56.Kilian C, Lemp JM, Probst C. Who benefits from alcohol screening and brief intervention? A mini-review on socioeconomic inequalities with a focus on evidence from the United States. Addict Behav. 2023;145:107765.
  57. 57.Parthasarathy S, Chi FW, Metz V, et al. Disparities in the receipt of alcohol brief intervention: the intersectionality of sex, age, and race/ethnicity. Addiction. 2023;118(7):1258-1269.
  1. 1.Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147-1157.
  2. 2.American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081.
  3. 3.Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019;2(1):e187399.
  4. 4.Ladapo JA, Larochelle MR, Chen A, et al. Physician prescribing of opioids to patients at increased risk of overdose from benzodiazepine use in the United States. JAMA Psychiatry. 2018;75(6):623-630.
  5. 5.US Food and Drug Administration. FDA requiring boxed warning updated to improve safe use of benzodiazepine drug class includes potential for abuse, addiction, and other serious risks. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class
  6. 6.Liu S, O’Donnell J, Gladden RM, et al. Trends in nonfatal and fatal overdoses involving benzodiazepines—38 states and the District of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep. 2021;70(34):1136-1141.
  7. 7.Diagnostic and Statistical Manual of Mental Disorders. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text revision. American Psychiatric Association; 2022.
  8. 8.Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97-106.
  9. 9.Blanco C, Han B, Jones CM, et al. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States. J Clin Psychiatry. 2018;79(6):18m12174.
  10. 10.McCabe SE, Schulenberg JE, Wilens TE, et al. Transitions in prescription benzodiazepine use and misuse and in substance use disorder symptoms through age 50. Psychiatr Serv. 2023;74(11):1154-1162.
  11. 11.National Institute on Drug Abuse. Drug overdose deaths: facts and figures. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
  12. 12.American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management. Anesthesiology. 2010;112(4):810-833.
  13. 13.Cashin AG, Wand BM, O’Connell NE, et al. Pharmacological treatments for low back pain in adults: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2023(4):CD013815.
  14. 14.Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. National Institute for Health and Care Excellence; 2021.
  15. 15.Pain Management Best Practices Inter-Agency Task Force report: updates, gaps, inconsistencies, and recommendations. US Department of Health and Human Services; 2019.
  16. 16.Lape EC, Powers JM, Hooker JE, et al. Benzodiazepine use and dependence in relation to chronic pain intensity and pain catastrophizing. J Pain. 2023;24(2):345-355.
  17. 17.Breilmann J, Girlanda F, Guaiana G, et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2019(3):CD010677.
  18. 18.Work Group on Panic Disorder. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry. 1998;155(5 suppl):1-34.
  19. 19.Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. 2020;11:595584.
  20. 20.National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management. https://www.nice.org.uk/guidance/cg113
  21. 21.Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768-777.
  22. 22.Brandt J, Bressi J, Lê ML, et al. Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review. EClinicalMedicine. 2024;70:102507.
  23. 23.Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349.
  24. 24.Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339-351.
  25. 25.Ogbonna CI, Lembke A. Tapering patients off of benzodiazepines. Am Fam Physician. 2017;96(9):606-610.
  26. 26.Kale N. Urine drug tests: ordering and interpreting results. Am Fam Physician. 2019;99(1):33-39.
  27. 27.McNeely J, Wu LT, Subramaniam G, et al. Performance of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med. 2016;165(10):690-699.
  28. 28.Baandrup L, Ebdrup BH, Rasmussen JØ, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018(3):CD011481.
  29. 29.Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol. 1989;9(6):412-416.
  30. 30.Gould RL, Coulson MC, Patel N, et al. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204(2):98-107.
  31. 31.Sacarny A, Safran E, Steffel M, et al. Effect of pharmacist email alerts on concurrent prescribing of opioids and benzodiazepines by prescribers and primary care managers. JAMA Health Forum. 2022;3(9):e223378.
  1. 1.Cornelius ME, Loretan CG, Jamal A, et al. Tobacco product use among adults - United States, 2021. MMWR Morb Mortal Wkly Rep. 2023;72(18):475-483.
  2. 2.Xu X, Shrestha SS, Trivers KF, et al. U.S. healthcare spending attributable to cigarette smoking in 2014. Prev Med. 2021;150:106529.
  3. 3.National Institute on Drug Abuse. Tobacco, nicotine, and e-cigarettes research report. Do people with mental illness and substance use disorders use tobacco more often? https://nida.nih.gov/publications/research-reports/tobacco-nicotine-e-cigarettes/do-people-mental-illness-substance-use-disorders-use-tobacco-more-often
  4. 4.Birdsey J, Cornelius M, Jamal A, et al. Tobacco product use among U.S. middle and high school students—National Youth Tobacco Survey. MMWR Morb Mortal Wkly Rep. 2023;72(44):1173-1182.
  5. 5.Murthy VH. e-Cigarette use among youth and young adults: a major public health concern. JAMA Pediatr. 2017;171(3):209-210.
  6. 6.US Dept of Health and Human Services, Centers for Disease Control and Prevention. e-Cigarette use among youth and young adults. A report of the Surgeon General. https://www.ncbi.nlm.nih.gov/books/NBK538680/
  7. 7.Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of tobacco smoking: a review. JAMA. 2022;327(6):566-577.
  8. 8.US Dept of Health and Human Services. The health consequences of smoking—50 years of progress. A report of the surgeon general. https://www.ncbi.nlm.nih.gov/books/NBK179276/pdf/Bookshelf_NBK179276.pdf
  9. 9.Cao DJ, Aldy K, Hsu S, et al. Review of health consequences of electronic cigarettes and the outbreak of electronic cigarette, or vaping, product use-associated lung injury. J Med Toxicol. 2020;16(3):295-310.
  10. 10.National Academies of Sciences Engineering Medicine. Public health consequences of e-cigarettes. https://nap.nationalacademies.org/read/24952/chapter/1
  11. 11.Patel MS, Patel SB, Steinberg MB. Smoking cessation. Ann Intern Med. 2021;174(12):ITC177-ITC192.
  12. 12.Gaddey HL, Dakkak M, Jackson NM. Smoking cessation interventions. Am Fam Physician. 2022;106(5):513-522.
  13. 13.US Dept of Health and Human Services. Treating tobacco use and dependence: 2008 update. https://www.ncbi.nlm.nih.gov/books/NBK63952/
  14. 14.Krist AH, Davidson KW, Mangione CM, et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(3):265-279.
  15. 15.US Dept of Health and Human Services. Smoking cessation. A report of the Surgeon General. https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf
  16. 16.Hartmann-Boyce J, Livingstone-Banks J, et al. Behavioural interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2021(1):CD013229.
  17. 17.Schultz ME, Fronk GE, Jaume N, et al. Stressor-elicited smoking and craving during a smoking cessation attempt. J Psychopathol Clin Sci. 2022;131(1):73-85.
  18. 18.Leone FT, Zhang Y, Evers-Casey S, et al. Initiating pharmacologic treatment in tobacco-dependent adults. an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;202(2):e5-e31.
  19. 19.Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev. 2023(9):CD015226.
  20. 20.Jewett C, Jacobs A. FDA aims to cut down on smoking by slashing nicotine levels in cigarettes. New York Times. June 21, 2022. https://www.nytimes.com/2022/06/21/health/fda-nicotine-cigarettes.html
  21. 21.Richtel M, Jacobs A. FDA orders Juul to stop selling e-cigarettes. New York Times. June 23, 2023. https://www.nytimes.com/2022/06/23/health/fda-juul-ecigarettes-ban.html
  22. 22.Hartmann-Boyce J, Cahill K, Hatsukami D, et al. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev. 2012(8):CD007072.
  23. 23.Hatsukami DK, Jorenby DE, Gonzales D, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther. 2011;89(3):392-399.
  1. 1.Substance Abuse and Mental Health Services Administration. 2021 NSDUH Annual National Report. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report
  2. 2.American Society of Addiction Medicine. Definition of addiction. addiction. https://www.asam.org/docs/default-source/quality-science/asam’s-2019-definition-of-addiction-(1).pdf?sfvrsn=b8b64fc2_2
  3. 3.United Nations Office on Drugs and Crime. The non-medical use of prescription drugs. Policy direction issues. Discussion paper. https://www.unodc.org/documents/drug-prevention-and-treatment/nonmedical-use-prescription-drugs.pdf
  4. 4.National Institute on Drug Abuse. Words matter—terms to use and avoid when talking about addiction. https://nida.nih.gov/nidamed-medical-health-professionals/health-professions-education/words-matter-terms-to-use-avoid-when-talking-about-addiction
  5. 5.Bremer W, Plaisance K, Walker D, et al. Barriers to opioid use disorder treatment: a comparison of self-reported information from social media with barriers found in literature. Front Public Health. 2023;11:1141093.
  6. 6.Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217-238.
  7. 7.Substance Abuse and Mental Health Services Administration; Office of the Surgeon General. Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. US Dept of Health and Human Services; November 2016.
  8. 8.Dowell D, Ragan KR, Jones CM, et al. CDC clinical practice guideline for prescribing opioids for pain—United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95.
  9. 9.Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther. 2000;17(2):70-83.
  10. 10.Salsitz EA. Chronic pain, chronic opioid addiction: a complex nexus. J Med Toxicol. 2016;12(1):54-57.
  11. 11.Jones KF, Mason DJ. The false dichotomy of pain and opioid use disorder. JAMA Health Forum. 2022;3(4):e221406.
  12. 12.Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-576.
  13. 13.Cheatle MD, Compton PA, Dhingra L, et al. Development of the revised Opioid Risk Tool to predict opioid use disorder in patients with chronic nonmalignant pain. J Pain. 2019;20(7):842-851.
  14. 14.Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741-1748.
  15. 15.St Marie B. Assessing patients’ risk for opioid use disorder. AACN Adv Crit Care. 2019;30(4):343-352.
  16. 16.Klimas J, Gorfinkel L, Fairbairn N, et al. Strategies to identify patient risks of prescription opioid addiction when initiating opioids for pain: a systematic review. JAMA Netw Open. 2019;2(5):e193365.
  17. 17.Rath JM, Perks SN, Vallone DM, et al. Educating young adults about opioid misuse: evidence from a mass media intervention. Int J Environ Res Public Health. 2021;19(1):22.
  18. 18.Altekruse SF, Cosgrove CM, Altekruse WC, et al. Socioeconomic risk factors for fatal opioid overdoses in the United States: findings from the mortality disparities in American Communities Study (MDAC). PLoS One. 2020;15(1):e0227966.
  19. 19.National Institute on Drug Abuse. Opioid Risk Tool – OUD (ORT-OUD). https://nida.nih.gov/nidamed-medical-health-professionals/screening-tools-resources/opioid-risk-tool-oud-ort-oud
  20. 20.Chang YP, Compton P. Management of chronic pain with chronic opioid therapy in patients with substance use disorders. Addict Sci Clin Pract. 2013;8(1):21.
  21. 21.Larson MJ, Paasche-Orlow M, Cheng DM, et al. Persistent pain is associated with substance use after detoxification: a prospective cohort analysis. Addiction. 2007;102(5):752-760.
  22. 22.Ducharme J, Moore S. Opioid use disorder assessment tools and drug screening. Mo Med. 2019;116(4):318-324.
  23. 23.Patnode CD, Perdue LA, Rushkin M, et al. Screening for unhealthy drug use. JAMA. 2020;323(22):2310-2328.
  24. 24.American Academy of Family Physicians. Opioid use disorder (OUD): screening. https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/oud.html
  25. 25.McNeely J, Cleland CM, Strauss SM, et al. Validation of self-administered single-item screening questions (SISQS) for unhealthy alcohol and drug use in primary care patients. J Gen Intern Med. 2015;30(12):1757-1764.
  26. 26.Centers for Disease Control and Prevention. Opioid use disorder: diagnosis. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-diagnosis.html
  27. 27.Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text revision. American Psychiatric Association; 2022.
  28. 28.Jones CM, Han B, Baldwin GT, et al. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6(8):e2327488.
  29. 29.Carley JA, Oesterle T. Therapeutic approaches to opioid use disorder. Int J Gen Med. 2021;14:2305-2311.
  30. 30.Barriers to broader use of medications to treat opioid use disorder. In: Mancher M, Leshner AI, eds. Medications for Opioid Use Disorder Save Lives. National Academies Press; 2019.
  31. 31.Krawczyk N, Rivera BD, Jent V, et al. Has the treatment gap for opioid use disorder narrowed in the U.S.? Int J Drug Policy. 2022;110:103786.
  32. 32.Barbosa Neto JO, Garcia MA, Garcia JBS. Revisiting methadone: pharmacokinetics, pharmacodynamics and clinical indication. Rev Dor. 2015;16(1):60-66.
  33. 33.Substance Abuse and Mental Health Services Administration. TIP 63: medications for opioid use disorder. https://store.samhsa.gov/product/tip-63-medications-opioid-use-disorder/pep21-02-01-002
  34. 34.Santo T, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence. JAMA Psychiatry. 2021;78(9):979-993.
  35. 35.Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.
  36. 36.McGinty EE, Stone EM, Kennedy-Hendricks A, et al. Medication for opioid use disorder. Ann Intern Med. 2020;173(2):160-162.
  37. 37.Substance Abuse and Mental Health Services Administration. Waiver elimination (MAT Act). https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act
  38. 38.US Food and Drug Administration. Primary care providers can prescribe with confidence. https://www.fda.gov/drugs/prescribe-confidence/primary-care-providers-can-prescribe-confidence
  39. 39.Darke S, Larney S, Farrell M. Yes, people can die from opiate withdrawal. Addiction. 2017;112(2):199-200.
  40. 40.Bryce C. Lofexidine (Lucemyra) for treatment of opioid withdrawal symptoms. Am Fam Physician. 2019;99(6):392-394.
  41. 41.Kowalczyk WJ, Phillips KA, Jobes ML, et al. Clonidine maintenance prolongs opioid abstinence and decouples stress from craving in daily life: a randomized controlled trial with ecological momentary assessment. Am J Psychiatry. 2015;172(8):760-767.
  42. 42.Schiller EY, Goyal A, Mechanic OJ. Opioid overdose. StatPearls. http://www.ncbi.nlm.nih.gov/books/NBK470415/
  43. 43.National Institute on Drug Abuse. Naloxone drug facts. https://nida.nih.gov/publications/drugfacts/naloxone
  44. 44.NARCAN (naloxone hydrochloride) nasal spray. NARCAN (naloxone hydrochloride) nasal spray. Package insert. Adapt Pharma, Inc.; 2023.
  45. 45.Berg S. Lifesaving naloxone should be available almost everywhere. American Medical Association. https://www.ama-assn.org/delivering-care/overdose-epidemic/lifesaving-naloxone-should-be-available-almost-everywhere
  46. 46.US Food and Drug Administration. New recommendations for naloxone. https://www.fda.gov/drugs/drug-safety-and-availability/new-recommendations-naloxone

Current edition

Hepatitis Overview

Hepatitis Overview

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.